Who are Pretomanid (Pa)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fexinidazole, Solosec, Pylera, BISMUTH SUBCITRATE POTASSIUM, Tindamax, Metro I.V. In Plastic Container.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pretomanid-pa.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Pretomanid (Pa) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pretomanid (Pa) (Pretomanid (Pa)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: nitroimidazole. Area: Infectious Diseases.

phase 3 nitroimidazole dihydrofolate reductase (DHFR) Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

Pretomanid (Pa) (Pretomanid (Pa)) — Wuhan Pulmonary Hospital. Pretomanid is a prodrug that is converted into its active form, which inhibits the enzyme dihydrofolate reductase (DHFR) in Mycobacterium tuberculosis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pretomanid (Pa) TARGET	Pretomanid (Pa)	Wuhan Pulmonary Hospital	phase 3	nitroimidazole	dihydrofolate reductase (DHFR)
Fexinidazole	FEXINIDAZOLE	Sanofi	marketed	Nitroimidazole Antimicrobial [EPC]		2021-01-01
Solosec	SECNIDAZOLE	Evofem Inc	marketed	Nitroimidazole Antimicrobial [EPC]		2017-01-01
Pylera	BISMUTH SUBCITRATE		marketed	Nitroimidazole Antimicrobial [EPC]		2006-01-01
BISMUTH SUBCITRATE POTASSIUM	BISMUTH SUBCITRATE POTASSIUM		marketed	Nitroimidazole Antimicrobial [EPC]		2006-01-01
Tindamax	TINIDAZOLE	Mission Pharma	marketed	Nitroimidazole Antimicrobial [EPC]		2004-01-01
Metro I.V. In Plastic Container	METRONIDAZOLE	Baxter	marketed	Nitroimidazole Antimicrobial [EPC]		1963-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-02-02 — Metro I.V. In Plastic Container · 8877792 · Formulation · US
2028-02-19 — Metro I.V. In Plastic Container · 7893097 · Formulation · US
2028-06-27 — Metro I.V. In Plastic Container · 8658678 · Method of Use · US
2032-06-28 — Metro I.V. In Plastic Container · 9198858 · Method of Use · US
2032-06-28 — Metro I.V. In Plastic Container · 8946276 · Method of Use · US
2032-06-28 — Metro I.V. In Plastic Container · 10238634 · Formulation · US
2032-06-28 — Metro I.V. In Plastic Container · 10596155 · Formulation · US
2039-01-16 — Metro I.V. In Plastic Container · 12257236 · Formulation · US
2039-10-04 — Metro I.V. In Plastic Container · 11541035 · Formulation · US

Sponsor landscape (nitroimidazole class)

Laboratorio Elea Phoenix S.A. · 1 drug in this class
Wuhan Pulmonary Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pretomanid (Pa) — Competitive Intelligence Brief. https://druglandscape.com/ci/pretomanid-pa. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing